Correlating the Tumoral Metabolic Progression Index Measured by Serial FDG PET-CT and Apparent Diffusion Coefficient Measured by MRI to Patient's Outcome in Advanced Colorectal Cancer
Natural history of tumors is a poorly studied subject, the clinical evidence of some tumors
aggressiveness as opposed to some other's indolent behavior has never been formally assessed
in daily practice or in clinical studies and remains largely unpredictable. The patient's
populations are in fact a mix between different tumoral phenotypes that while carrying the
same apparent disease evolve with different outcomes.
We hypothesize that,in a population of patients with advanced colorectal cancer for which no
known effective therapy is available, measuring the spontaneous evolution of tumoral
metabolic progression index by serial FGD PET-CT and Diffusion MRI can show that tumor
growth rate is related to the patient's outcome, and that serial FDG PET-CT and Diffusion
MRI are able to measure it.
If the hypothesis is verified, this finding could:
- Allow to define therapeutic strategies according to the tumoral metabolic progression
- Limit the need for randomization in the early drug development phases as each patient
could be considered as his own control.
- To stratify patients according to their baseline metabolic growth rate in randomized
controlled trials with overall survival as an endpoint.
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Amélie Deleporte, MD
Jules Bordet Institute , Universite Libre De Bruxelles
Belgium: Federal Agency for Medicinal Products and Health Products